New CEO, new board chair, new funding for ImmPact Bio
Camarillo-based ImmPact Bio made multiple headlines with one announcement on Jan. 20: the a new CEO, a new board chair, and the closing of a $111 million Series B funding round. ImmPact, a biotechnology company developing cancer treatments based on chimeric antigen receptor (CAR) T-cell therapies, named Sumant Ramachandra as its new president and CEO. Read More →
Read More →Amgen inks drug development deal worth up to $1.9B
Thousand Oaks-based Amgen has reached an agreement with Generate Biomedicines, a Massachusetts-based therapeutics company, to research, discover and create protein therapeutics, the company announced Jan. 6. According to the agreement, Amgen, one of the largest biotech companies in the world, will pay $50 million up front to fund the initial five programs, with a potential Read More →
Read More →
Capsida’s new CEO hopes success is in the genes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →2021: The Year In Review
The Dec. 31 print edition of the Pacific Coast Business Times marks our annual Year In Review, featuring the biggest and best stories we published in 2021. Here is a look through our archives at the past year, a year marked by big deals, economic recovery and public health victories, but also by recurring waves Read More →
Read More →Amgen’s new asthma treatment gets FDA approval
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Capsida names new CEO
Capsida Biotherapeutics, a venture-backed Thousand Oaks company developing gene therapy treatments, announced the hiring of a new CEO on Dec. 7. In April, Capsida emerged from “stealth mode” and closed a $140 million series A funding round, one of the largest venture capital raises of the year in the region’s life sciences sector. Capsida is Read More →
Read More →MannKind reports higher revenue, lower losses in Q3
MannKind Corp. reported a substantial rise in revenue and a shrinking net loss in the third quarter of 2021 on Nov. 9, despite news since the quarter ended that the U.S. Food and Drug Administration will not yet approve a hypertension treatment the company is developing with United Therapeutics. MannKind, a Westlake Village-based biotechnology company Read More →
Read More →
